Clinical trials: Clopidogrel, completed
Claudication
Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease.
Hypothesis: Primary long full coverage stenting is superior to primary short spot stenting in the treatment of long (≥80 mm) femoropopliteal artery lesions.
- Trial name
- NCT01359423
- Testing
- Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long, short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- Yonsei University
Treatment of Acute Coronary Syndrome (ACS).
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital after an acute coronary syndrome (ACS)…
- Trial name
- REWINDER (NCT02190123)
- Testing
- ACS patients treated with OAP
- Where
- 15 sites in Belgium
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Coronary Heart Disease, Stable Angina Pectoris
Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index
The purpose of the trial is to take stable angina pectoris of coronary heart disease (CHD) as examples to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM). 1.
- Trial name
- NCT01502943
- Testing
- Louxiangdan Tongxin granules, Chixiangshen Tongxin granules, Western basis treatment
- Where
- 10 sites in China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Liaoning University of Traditional Chinese Medicine
Acute Coronary Syndrome, Acute Myocardial Infarction
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- VERONICA (NCT04654052)
- Testing
- Clopidogrel, Previous treatment
- Where
- 19 sites in Spain
- Volunteers
- 637 people
- Sponsor
- Fundación EPIC
Stable Coronary Artery Disease
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
- Trial name
- NCT01118325
- Testing
- ticagrelor, clopidogrel
- Where
- 13 sites in Japan, Philippines
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome, STEMI
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
The specific goal of this study is to determine whether the individualized approach and adjusting the dosage of the P2Y12 receptor inhibitors will improve the platelet inhibiton and the clinical outcome in patients with an ACS…
- Conditions
- Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI, PLATELET AGGREGATION
- Trial name
- SPARELIFE (NCT04369534)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Croatia
- Volunteers
- 120 people
- Sponsor
- University of Zagreb
Acute Coronary Syndrome
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
- Trial name
- NCT00830960
- Testing
- Prasugrel, Clopidogrel
- Where
- 19 sites in China, South Korea and 2 more
- Volunteers
- 720 people
- Sponsor
- Eli Lilly and Company
Healthy
Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered…
- Trial name
- NCT00650169
- Testing
- Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
Current guidelines recommend that patients with ACS undergoing stent implantation might be offered extended DAPT treatment for up to 30 months if necessary.
- Trial name
- OPT-BIRISK (NCT03431142)
- Testing
- Clopidogrel, Clopidogrel+aspirin
- Where
- 103 sites in China
- Volunteers
- 7,758 people
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Bypass Grafting
Comparing Point of Care Clotting Tests in the OR Versus Standard Laboratory Clotting Tests
The purpose of this study is determine the agreement of point of care (POC) clotting tests (INR and aPTT) by the POC device by Hemochron Jr versus standard laboratory clotting tests (INR and aPTT) in patients undergoing elective…
- Trial name
- NCT00892905
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McMaster University
Platelet Reactivity
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
Platelets are a major component of clot formation which can lead to clotting events such as heart attack. During treatment for a heart attack, doctors try to remove this blockage as quickly as possible so that the heart can…
- Trial name
- NCT00827346
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Coronary Artery Disease
STEEL Percutaneous Coronary Intervention
The principal hypothesis of this study is that two different maintenance regimens of ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte adenosine reuptake compared to clopidogrel in patients…
- Trial name
- STEEL-PCI (NCT02327624)
- Testing
- Clopidogrel, Ticagrelor 60, Ticagrelor 90
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Coronary Artery Disease
Simplified Anti-Thrombotic Therapy for FFR
Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR calculation, no study has evaluated the optimal anti-thrombotic regimen in patients undergoing FFR.
- Trial name
- SMART-FFR (NCT02384070)
- Testing
- FFR, Aspirin, Clopidogrel
- Volunteers
- 300 people
- Sponsor
- Odessa Heart Institute
Peripheral Arterial Disease (PAD)
Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interests in patients with peripheral arterial disease (PAD) Secondary objectives: To…
- Trial name
- NCT00862420
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 431 people
- Sponsor
- Sanofi
High Bleeding Risk, Coronary Artery Disease
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with…
- Conditions
- High Bleeding Risk, Coronary Artery Disease, PCI
- Trial name
- MASTER DAPT (NCT03023020)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- 138 sites in Argentina, Australia and 28 more
- Volunteers
- 4,579 people
- Sponsor
- ECRI bv
Acute Coronary Syndrome, Cardiovascular Diseases
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy.
- Trial name
- ADAPT (NCT02508116)
- Testing
- CYP2C19 genotyping
- Where
- 2 sites in United States
- Volunteers
- 509 people
- Sponsor
- University of Pennsylvania
Platelet Aggregation Inhibitors, NSTEACS
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation…
- Trial name
- NCT00325390
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 800 people
- Sponsor
- Sanofi
Arterial Occlusive Diseases
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
Primary objective: To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100 mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in patients receiving a below knee…
- Trial name
- NCT00174759
- Testing
- Clopidogrel
- Where
- 14 sites in Australia, Austria and 12 more
- Volunteers
- 1,460 people
- Sponsor
- Sanofi
Aneurysm Cerebral, Endovascular Procedures
Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling
Comparison of duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms
- Trial name
- NCT05257824
- Testing
- Aspirin 100mg, Clopidogrel 75mg
- Where
- 8 sites in South Korea
- Volunteers
- 528 people
- Sponsor
- Seoul National University Bundang Hospital
Kidney Failure, Hemodialysis Fistula Thrombosis
Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis
The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. This study was originally registered as NCT00067119 which included two protocols, this one and the GRAFT study)
- Trial name
- FISTULA (NCT03289520)
- Testing
- Clopidogrel
- Where
- 9 sites in United States
- Volunteers
- 877 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)